NCT03107416Active, not recruitingPhase 1/2
Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells
Phase I/II Study of Transarterial Hepatic Embolization With Bumetanide in Unresectable Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 5 May 2026
Brief summary (registry, in English)
The purpose of this study is to test the safety of Bumetanide , at different doses to find out what effects, if any, it has on people who undergo tumor TAE as part of their regular care. Bumetanide is a commonly used medication to reduce the amount of water in the body.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 5 Apr 2017
- Start date
- 5 Apr 2017
- Primary completion date
- 5 Apr 2027
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT03107416
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 30
- From 5 Apr 2017 to the primary completion date, 5 Apr 2027
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Documented hypersensitivity to bumetanide or sulfonamides
- High risk for post-embolization hepatic failure:
- °Child's C cirrhosis
- °\> 80% liver involvement by tumor
- Contraindication to angiography/embolization including:
- Patients cannot receive contrast:
- Severe allergic reaction to contrast despite premedication
- Poor renal function not on dialysis
- Other, based on judgment of the investigator
Other
- Women who are pregnant or lactating
- Patients with resectable HCC
- ECOG score 2
- Main portal vein tumor thrombus
- BCLC D = patients with distant metastasis
Who the study is looking for
- Patients with diagnoses of HCC according to European Association for the Study of Liver disease (EASL) criteria for diagnosis (See Appendix 1). Regional lymphadenopathy will be allowed.
- Any virus status accepted (e.g. Hepatitis C etc.)
- Any prior liver treatment
- Patients within unresectable HCC
- At least 18 years old
- ECOG performance status 0 or 1
- Radiographically measurable disease per mRECIST 1.1
- Meets standard of care to undergo embolization
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan Kettering Basking Ridge (Consent and follow-up only) Coordinator of this site? Confirm its status | Basking Ridge | United States | Unknown status |
| Memorial Sloan Kettering Westchester (Consent and follow-up only) Coordinator of this site? Confirm its status | Harrison | United States | Unknown status |
| Memorial Sloan Kettering Monmouth (Consent and follow-up only) Coordinator of this site? Confirm its status | Middletown | United States | Unknown status |
| Memorial Sloan Kettering Bergen (Consent and follow-up only) Coordinator of this site? Confirm its status | Montvale | United States | Unknown status |
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.